erlotinib hydrochloride has been researched along with xav939 in 2 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (xav939) | Trials (xav939) | Recent Studies (post-2010) (xav939) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 186 | 0 | 179 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | xav939 (IC50) |
|---|---|---|---|
| Chain A, Tankyrase-1 | Homo sapiens (human) | 0.011 | |
| Chain A, Tankyrase-1 | Homo sapiens (human) | 0.011 | |
| Poly [ADP-ribose] polymerase tankyrase-1 | Homo sapiens (human) | 0.0656 | |
| Poly [ADP-ribose] polymerase 1 | Homo sapiens (human) | 0.9968 | |
| Protein Wnt-3a | Mus musculus (house mouse) | 0.078 | |
| Protein Wnt-3a | Homo sapiens (human) | 0.078 | |
| Protein mono-ADP-ribosyltransferase PARP14 | Homo sapiens (human) | 5.8942 | |
| Vesicular acetylcholine transporter | Rattus norvegicus (Norway rat) | 0.015 | |
| Poly [ADP-ribose] polymerase tankyrase-2 | Homo sapiens (human) | 0.052 | |
| Poly [ADP-ribose] polymerase 2 | Homo sapiens (human) | 0.0792 | |
| Protein mono-ADP-ribosyltransferase PARP4 | Homo sapiens (human) | 4.3776 | |
| Protein mono-ADP-ribosyltransferase PARP3 | Homo sapiens (human) | 0.8354 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Botting, GM; Fong, JT; Jacobs, RJ; Moravec, DN; Nlend, M; Puri, N; Uppada, SB | 1 |
| Botting, GM; Chhabra, G; Nlend, M; Puri, N; Rastogi, I | 1 |
2 other study(ies) available for erlotinib hydrochloride and xav939
| Article | Year |
|---|---|
Alternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-Met inhibitor resistance in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; Indoles; Lung Neoplasms; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction; Sirolimus; Sulfonamides; TOR Serine-Threonine Kinases; Wnt Proteins | 2013 |
Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; GATA6 Transcription Factor; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Heterocyclic Compounds, 3-Ring; Humans; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; TOR Serine-Threonine Kinases; Wnt Signaling Pathway | 2015 |